| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-11-04 | Hoopika Biotech (Austria) | €20 million ($27.5 million) | series B financing round | Sofinnova Partners (France) Forbion Capital Partners (The Netherlands) Boehringer Ingelheim Venture Fund (Germany) Takeda Ventures (USA - CA) BioMedPartners (Switzerland) | Cancer - Oncology - Infectious diseases | Series B financing round |
| 2013-10-31 | Ablynx (Belgium) | €1.68 million | grant | Flemish Agency for Innovation by Science and Technology (IWT) (Belgium) | Infectious diseases - Respiratory diseases | Grant |
| 2013-10-30 | Santhera Pharmaceuticals (Switzerland) | CHF 10 Million (€ 8 million) | Rare diseases - Neurodegenerative diseases - Neuromuscular diseases - Ophtalmological diseases | Credit line | ||
| 2013-10-30 | Transgene | grant | National Institutes of Health (NIH) (USA) | Infectious diseases | Grant | |
| 2013-10-29 | Epigenomics (Germany) | € 3.3 million | private placement | Biochain (USA), institutional investors in Europe and the U.S. | Diagnostic - Cancer - Oncology | Capital increase |
| 2013-10-16 | Theravectys (France) | €14.7 million | financing round | Tethys (France), Financière IDAT (France), FGP Capital (France), other private investors | Infectious diseases | Fundraising |
| 2013-10-15 | Nosopharm (France) | €870,000 | grant | Armaments Procurement Agency (DGA) (France), General Directorate for Competitiveness, Industries and Services (Ministry for Industrial Renewal) (France) | Infectious diseases | Grant |
| 2013-10-15 | CV genes-at-target consortium - (Horizon Discovery - UK, Deutsches Herzzentrum München - Germany, University of Leicester - UK, Oxford University - UK, UMC Utrecht - The Netherlands, LMU Munich - Germany, University of Lübeck - Germany, Bioceros - The Netherlands, Clinical Gene Networks, European Screening Port, 4SC Discovery - Germany, Genedata. | €5.75 million ($7.8 million) | grant | European Commission’s Seventh Framework Program (FP7) | Cardiovascular diseases | Grant |
| 2013-10-14 | Lundbeck (Denmark) | DKK 5 million (€0.73 million) | grant | The Michael J. Fox Foundation - MJFF (USA) | Neurodegenerative diseases | Grant |
| 2013-10-11 | Hybrigenics (France) | € 1.3 million | private placement | Pradeyrol Development (France) | Private placement | |
| 2013-10-10 | Cytos Biotechnology (Switzerland) | up to CHF 17.6 million (€ 14.3 million) | capital increase | Abingworth (UK), venBio (USA), Aisling Capital (USA), Amgen (USA) | Allergic diseases - Immunological diseases | Capital increase |
| 2013-10-09 | Pharming (The Netherlands) | private placement | Rare diseases | Private placement | ||
| 2013-10-09 | Oxford Nanopore Technologies (UK) | £40 million (€ 47.2 million) | private placement | new and existing investors in the US, UK and mainland Europe | Private placement | |
| 2013-10-07 | Pharmalink (Sweden) | SEK 96 million (€ 11 million) | share issue | Industrifonden (Sweden), Investinor (Norway), private investors | Kidney diseases - Renal diseases - Transplantation | Fundraising |
| 2013-10-07 | Defymed (France) | € 1.2 million | Centre Européen d\'Etude du Diabète (CEED) (France), Fonds Lorrain des Matériaux (France) | Metabolic diseases | Fundraising | |
| 2013-10-03 | Merus (The Netherlands) | €47.6 million | Series B financing round | Johnson & Johnson Development Corporation (JJDC) (USA) Novartis Venture Fund (Switzerland) Pfizer Venture Investments (USA) Bay City Capital (USA) LSP (The Netherlands) Aglaia Oncology Fund (The Netherlands) |
Cancer - Oncology | Series B financing round |
| 2013-10-02 | Opsona Therapeutics (Ireland) | €36 million | Series C financing round | Novartis Venture Fund (Switzerland), Fountain Healthcare Partners (Ireland), Roche Venture Fund (Switzerland), Seroba Kernel Life Sciences (Ireland), BB Biotech Ventures (Switzerland), Sunstone Capital (Denmark), Baxter Ventures (USA), Amgen Ventures (USA), EMBL Ventures (Germany), Omnes Capital (France) | Inflammatory diseases | Series C financing round |
| 2013-09-25 | Consortium 3D-NET ( KalVista Pharmaceuticals (UK) University College Dublin (Ireland), Universidad de Valladolid (Spain), RenaSci Ltd (UK) and Gadea Grupo Farmacéutico (Spain)) | €1.66 million | grant | European Commission’s Seventh Framework Program (FP7) | Ophtalmological diseases | Grant |
| 2013-09-25 | Bind Therapeutics (USA - MA) | $70,5 million | IPO | Cancer - Oncology | IPO | |
| 2013-09-24 | Consortium Elimox (OxThera AB (Sweden), Cobra Biologics (UK), SymbioPharm (Germany), Ergomed Clinical Research (UK), Universitätsklinikum Bonn (Germany), Hospices Civils de Lyon, (France), University College London Hospitals NHS Foundation Trust (UK), Galenica (Sweden), K.A.B.S. Laboratories (Canada), Medizinisches Versorgumszentrum Institute für Microökologie (Germany), TNO (Netherlands) and Bio-Images Research (UK) | €2.19 million | grant | European Commission’s Seventh Framework Program (FP7) | Rare diseases - Kidney diseases - Renal diseases | Grant |
